European Study Shows Promise In Reducing Recurrence and Spread In Breast Cancer

Even with early detection, some cancers are more aggressive and fatal than others.  Triple negative breast cancer (TNBC) which accounts for 10 to 15% of all breast cancers is one such example.  TNBC affects approximately 225,000 patients annually and around half of these patients will develop local recurrences or metastases elsewhere in the body, regardless of the treatment they receive.  TNBC tends to grow and spread faster than other types of breast cancer and has worse outcomes.

A new study out of the University of Louvain in Belgium claims that the supplement Mitoquinone mesylate, when combined with a carefully dosed cocktail of standard chemotherapies, reduces metastases by 80% and the incidence of local recurrences of human breast cancer by 75% in mice.  Conversely, most of the mice not treated suffered a local recurrence of their cancer or metastases.  Additionally, it showed only mild toxicity in the first human clinical trials with the primary side effects being nausea and vomiting.

Cancers are made up of several kinds of cancerous cells.  Some are actively proliferating when the cancer is found and treated, making them more measurable and sensitive to today's clinical treatments.  However, some cells remain alive but dormant, only to awaken later.  The study showed that Mitoquinone mesylate stops cancerous stem cells from awakening.

Because the three principal causes of cancer deaths are recurrences, cancer spread by metastases, and cellular resistance to treatment, Sonveaux of the University of Louvain and his colleagues believe Mioquinone mesylate is a breakthrough development in the reduction of TNBC-related deaths.  There is currently no other known molecule capable of acting like Mitoquinone mesylate, according to the researchers.

Because this study indicates such a major development, we have begun a more in-depth review of the study.  Within the next few weeks we will post our full review and share their findings on significant questions such as:

• What is the mechanism of action (ie. how does it work)?
• What dosage was used in the study?
• When and how to take it?
• Are there certain patients who should not use it?
• Does it have the potential to prevent metastasis and recurrence in other cancers?

If you would like to be notified when our review is complete, email us at customercare@vitopiahealth.com, putting "Breast Cancer Study" in the subject line.  Your email address will be kept strictly confidential. 

To read our prior health articles or learn how to access our full professional quality supplements and top recommended products, including Mitoquinone mesylate, visit our website at www.vitopiahealth.com.

To Your Health!

Mike Woodley, R.Ph., FAARNM, ABAAHP

Clinical Pharmacist